AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship ...

McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.

Novo Nordisk (NYSE:NVO) rose to its highest level in over two months Monday after a media report said hedge fund Parvus Asset ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

(Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

Pfizer's stock experienced a 2.66% increase on June 9, 2025, closing at $23.97, marking its second consecutive day of gains.

A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...